Table 3.
KEGG pathways.
| Profile BM | 6 miR down-regulated | KEGG pathways | p-value | genes | miRs | |
|---|---|---|---|---|---|---|
| 1. | Proteoglycans In Cancer (Hsa05205) | 6,9e-05 | 40 | 5 | ||
| 2. | Glioma (Hsa05214) | 6,9e-05 | 18 | 5 | ||
| 3. | Gap Junction (Hsa04540) | 6,9e-05 | 22 | 6 | ||
| 4. | Biotin Metabolism (Hsa00780) | 0,0002 | 1 | 1 | ||
| 5. | Erbb Signalling Pathway (Hsa04012) | 0,0003 | 24 | 5 | ||
| 6. | Renal Cell Carcinoma (Hsa05211) | 0,0004 | 19 | 5 | ||
| 7. | Neurotrophin Signalling Pathway (Hsa04722) | 0,0005 | 31 | 5 | ||
| 8. | Hepatitis B (Hsa05161) | 0,002 | 30 | 6 | ||
| 9. | Prostate Cancer (Hsa05215) | 0,002 | 24 | 6 | ||
| 10. | Phosphatidylinositol Signalling System (Hsa04070) | 0,002 | 16 | 5 | ||
| 11. | Glycosaminoglycan Biosynthesis - Chondroitin Sulfate / Dermatan Sulfate (Hsa00532) | 0,004 | 3 | 2 | ||
| 12. | Inositol Phosphate Metabolism (Hsa00562) | 0,007 | 13 | 4 | ||
| 13. | Lysine Degradation (Hsa00310) | 0,007 | 9 | 4 | ||
| 14. | Glycosphingolipid Biosynthesis - Lacto And Neolacto Series (Hsa00601) | 0,009 | 5 | 2 | ||
| 15. | Axon Guidance (Hsa04360) | 0,009 | 26 | 3 | ||
| 16. | Signalling Pathways Regulating Pluripotency Of Stem Cells (Hsa04550) | 0,009 | 28 | 5 | ||
| 17. | Chronic Myeloid Leukemia (Hsa05220) | 0,01 | 19 | 5 | ||
| 18. | Estrogen Signalling Pathway (Hsa04915) | 0,01 | 19 | 6 | ||
| 19. | Foxo Signalling Pathway (Hsa04068) | 0,01 | 30 | 5 | ||
| 20. | Thyroid Hormone Signalling Pathway (Hsa04919) | 0,01 | 21 | 5 | ||
| 21. | Pancreatic Cancer (Hsa05212) | 0,01 | 17 | 5 | ||
| 22. | MAPK Signalling Pathway (Hsa04010) | 0,01 | 47 | 5 | ||
| 23. | RNA Degradation (Hsa03018) | 0,01 | 20 | 6 | ||
| 24. | Acute Myeloid Leukemia (Hsa05221) | 0,01 | 15 | 5 | ||
| 25. | HIF-1 Signalling Pathway (Hsa04066) | 0,01 | 23 | 6 | ||
| 26. | Oocyte Meiosis (Hsa04114) | 0,02 | 22 | 5 | ||
| 27. | Endocytosis (Hsa04144) | 0,02 | 37 | 5 | ||
| 28. | TGF-Beta Signalling Pathway (Hsa04350) | 0,02 | 15 | 4 | ||
| 29. | Pathways In Cancer (Hsa05200) | 0,02 | 66 | 6 | ||
| 30. | P53 Signalling Pathway (Hsa04115) | 0,03 | 16 | 4 | ||
| 31. | PI3K-Akt Signalling Pathway (Hsa04151) | 0,04 | 55 | 6 | ||
| 32. | Melanoma (Hsa05218) | 0,04 | 17 | 5 | ||
| Profile BM | 4 miR up-regulated | KEGG pathway | p-value | genes | miRs | |
| 1. | ECM-Receptor Interaction (Hsa04512) | 2,1 e-11 | 10 | 2 | ||
| Profile A | 11 miR down-regulated | KEGG pathways | p-value | genes | miRs | |
| 1. | TGF-Beta Signalling Pathway (Hsa04350) | 2,0E-05 | 21 | 8 | ||
| 2. | Foxo Signalling Pathway (Hsa04068) | 1,1E-03 | 38 | 9 | ||
| 3. | Signalling Pathways Regulating Pluripotency Of Stem Cells (Hsa04550) | 1,1E-03 | 36 | 10 | ||
| 4. | Regulation Of Actin Cytoskeleton (Hsa04810) | 7,9E-03 | 55 | 10 | ||
| 5. | Thyroid Hormone Signalling Pathway (Hsa04919) | 7,9E-03 | 26 | 10 | ||
| 6. | Amphetamine Addiction (Hsa05031) | 1,0E-02 | 18 | 9 | ||
| 7. | Estrogen Signalling Pathway (Hsa04915) | 1,0E-02 | 27 | 10 | ||
| 8. | Choline Metabolism In Cancer (Hsa05231) | 1,2E-02 | 29 | 10 | ||
| 9. | Erbb Signalling Pathway (Hsa04012) | 1,4E-02 | 25 | 9 | ||
| 10. | Ras Signalling Pathway (Hsa04014) | 1,6E-02 | 48 | 10 | ||
| 11. | Thyroid Hormone Synthesis (Hsa04918) | 1,9E-02 | 14 | 9 | ||
| 12. | Ubiquitin Mediated Proteolysis (Hsa04120) | 2,3E-02 | 32 | 10 | ||
| 13. | Proteoglycans In Cancer (Hsa05205) | 2,3E-02 | 44 | 10 | ||
| 14. | Wnt Signalling Pathway (Hsa04310) | 3,3E-02 | 30 | 10 | ||
| 15. | Axon Guidance (Hsa04360) | 3,5E-02 | 29 | 10 | ||
| 16. | Prolactin Signalling Pathway (Hsa04917) | 3,7E-02 | 19 | 8 | ||
| 17. | Insulin Signalling Pathway (Hsa04910) | 3,7E-02 | 35 | 10 | ||
| 18. | Neurotrophin Signalling Pathway (Hsa04722) | 4,7E-02 | 29 | 9 | ||
| Profile A | 3 miR up-regulated | KEGG pathway | p-value | genes | miRs | |
| 1. | Thyroid Hormone Signalling Pathway (Hsa04919) | 6,9E-03 | 6 | 2 |
KEGG pathways involving the dysregulated miRs. The p-value was calculated by DIANA miRPath v.3 software.